Could an allergy pill and diabetes drug fix MS nerve damage?
NCT ID NCT05131828
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 trial tested whether combining two common drugs—metformin (for diabetes) and clemastine (an antihistamine)—can help repair the protective lining of nerve cells in people with relapsing-remitting multiple sclerosis. The 70 participants continued their usual MS treatments while taking the combo or a placebo for 24 weeks. Researchers measured changes in nerve signals to see if the drugs promote repair.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
metformin and clemastine combination
What this could lead to
If it works, this could point toward a treatment that repairs nerve damage in multiple sclerosis, potentially slowing or reversing disability progression.
What could go wrong
This is a small, early-phase trial (70 people) focused on measuring nerve signals, not clinical improvement. The drugs may not show a clear benefit, and results may not apply to all MS patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING - REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrooke's Hospital
Cambridge, United Kingdom